Carcinoembryonic Antigen (CEA, CD66e) BioAssay(TM) ELISA Kit

Carcinoembryonic antigen (CEA) is a cell-surface 200-kd glycoprotein. In 1969, it was reported that plasma CEA was elevated in 35 of 36 patients with adenocarcinoma of the colon and that CEA titers decreased after successful surgery. Normal levels were observed in all patients with other forms of cancer or benign diseases. Subsequent studies have not confirmed these initial findings, and it is now understood that elevated levels of CEA are found in many cancers. Increased levels of CEA are observed in more than 30% of patients with cancer of the lung, liver, pancreas, breast, colon, head or neck, bladder, cervix, and prostate. Elevated plasma levels are related to the stage and extent of the disease, the degree of differentiation of the tumor, and the site of metastasis. CEA is also found in normal tissue.\n\nIntended Use: \nThe CEA enzyme immunoassay test kit is intended for the quantitative determination of CEA concentration in human serum.\n\nPrinciple of the Test:\nThe CEA Quantitative Test Kit is based on a solid phase enzyme-linked immunosorbent assay. The assay system utilizes one monoclonal anti-CEA antibody for solid phase (microtiter wells) immobilization and another mouse monoclonal anti-CEA antibody in the antibody-enzyme (horseradish peroxidase) conjugate solution. The standards and test specimen (serum) are added to the CEA antibody coated microtiter wells. Then CEA antibody labeled with horseradish peroxidase (conjugate) is added. If human CEA is present in the specimen, it will combine with the antibody on the well and the enzyme conjugate resulting in the CEA molecules being sandwiched between the solid phase and enzyme-linked antibodies. After 1 hour incubation at room temperature, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of 2N HCl. The color is changed to yellow and measured spectrophotometrically at 450 nm. The concentration of CEA is directly proportional to the color intensity of the test sample.\n\nDetection Range: 0-120ng/ml\n\nSpecificity: 98.7%\n\nSensitivity: 1.0ng/ml\n\nKit Components:\nMicrotiter Plate, 1x96wells\nCEA Standard 0ng/ml, 2x500ul\nCEA Standard 3ng/ml, 2x500ul\nCEA Standard 12ng/ml, 2x500ul\nCEA Standard 30ng/ml, 2x500ul\nCEA Standard 60ng/ml, 2x500ul\nCEA Standard 120ng/ml, 2x500ul\nEnzyme Conjugate Reagent, 1x12 ml\nSubstrate TMB, 1x12ml\nStop Solution, 1x12ml\nWash Buffer Concentrate (50X), 1x15ml\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

167549

Size

96Tests

Applications

ELISA

References

1. Gold P, Freedman S O. Demonstration of tumor specific antigen in human colonic carcinomata by immunologic tolerance and absorption techniques. J Exp Med 1965;127:439-462. 2. Thompson D P M, Krupey J, Freedman S O, et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA 1969;64:161-167. 3. Schwartz M K. Tumor markers in diagnosis and screening. In: Ting S W, Chen J S, Schwartz M K, eds. Human tumor markers, Amsterdam: Elsevier Science, 1987;3-16. 4. Zamcheck N. and Martin E.W. Sequential Carcinoembryonic Antigen Levels in Pancreatic Cancer: Some Clinical Correlations. Cancer 1981;47:1620-1627. Mughal A.W., Hortobagyi G. N., Fritsche H.A., Buzdar A.U. Yap H-Y., and Blumenschein G.R. Serial Plasma Carcinoembryonic Antigen Measurements During Treatment of Metastatic Breast Cancer. JAMA 1983; 259:1881-1886.